Company news
Merck & Company, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Infinimmune Enters Collaboration with Merck to Discover Novel Human Antibody Therapeutics
March 31, 2026
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
March 30, 2026
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
March 29, 2026
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
March 25, 2026
Quotient Therapeutics Announces Collaboration with Merck to Discover Novel Drug Targets in Inflammatory Bowel Disease Using Somatic Genomics Platform Technology
March 24, 2026
Bambusa Therapeutics Appoints Todd James Chief Financial Officer
March 19, 2026
FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
March 18, 2026
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
March 17, 2026
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
March 16, 2026
TICE BCG (Merck) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
March 13, 2026
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
February 28, 2026
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
February 28, 2026
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
February 27, 2026
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
February 27, 2026
Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
February 26, 2026
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
February 25, 2026
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
February 25, 2026
Merck & Co Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Incubators, ICT, Technology Initiatives, Partnerships, Investments, Acquisitions, Network Map
February 25, 2026
Merck to Participate in the TD Cowen 46th Annual Health Care Conference
February 24, 2026
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
February 23, 2026
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
February 19, 2026
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
February 18, 2026
Health Canada Approves KEYTRUDA SC™, a subcutaneous formulation of pembrolizumab across multiple cancer indications
February 17, 2026
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
February 12, 2026
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
February 11, 2026
Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform
February 10, 2026
Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants
February 5, 2026
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
February 3, 2026
Global Glioma Market Growth Driven by Therapeutic Innovations and Aging Population
January 28, 2026
Merck Announces Second-Quarter 2026 Dividend
January 27, 2026
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
January 20, 2026
Merck and ChemLex Sign Memorandum of Understanding to Advance Automated Chemistry and Technological Innovation
January 20, 2026
TetraScience Appoints Matt Studney as Chief Customer Officer, Signaling Industry Shift Toward Platform-Based Scientific AI
January 14, 2026
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
January 7, 2026
Merck to Complete Acquisition of Cidara Therapeutics
January 7, 2026
Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3
January 7, 2026
Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
December 19, 2025
Rezubio Announces $20 Million Series A Financing to Advance the Membrane-Anchored Therapeutics Platform and Company Pipeline, with Lead Program in Obesity and Diabetes
December 18, 2025
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
December 17, 2025
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
December 12, 2025
BenchSci Extends ASCEND Agreement with Merck to Support Preclinical Disease Biology Research
December 9, 2025
Saskatchewan Adds CAPVAXIVE® to Publicly Funded Adult Immunization Program
December 8, 2025
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
December 4, 2025
Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
December 1, 2025
Merck to Participate in the Citi 2025 Global Healthcare Conference
November 26, 2025
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
November 26, 2025
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
November 24, 2025
Merck Recommends Rejection of Tutanota’s "Mini-Tender" Offer
November 21, 2025
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
November 21, 2025
Calls
The 5 newest of 32 calls. Every call is listed under its year.
- Merck & (NYSE:MRK) Q3 2026 Earnings Call
Oct 29, 2026
Transcript - Merck & (NYSE:MRK) Q2 2026 Earnings Call
Aug 4, 2026
Transcript - Merck & (NYSE:MRK) Q1 2026 Earnings Call
Apr 30, 2026
Transcript - Merck & (NYSE:MRK) Q4 2025 Earnings Call
Feb 3, 2026
Transcript - Merck & (NYSE:MRK) Q3 2025 Earnings Call
Oct 30, 2025
Transcript
Decks
The 5 newest of 99 decks. Every deck is listed under its year.
- Q3 2026 Earnings Presentation
Earnings · 28 slides · Oct 29, 2026
- Investor Day (October 2026)
Investor day · 27 slides · Oct 26, 2026
- Q2 2026 Earnings Presentation
Earnings · 33 slides · Aug 4, 2026
- International AIDS Conference (AIDS 2026) Investor Event
Conference · 34 slides · Aug 3, 2026
- Investor Day (June 2026)
Investor day · 39 slides · Jun 1, 2026